Published in Nat Rev Cardiol on October 26, 2010
Niacin Plus Statin to Prevent Vascular Events | NCT00120289
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE) | NCT00461630
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
The intersection between aging and cardiovascular disease. Circ Res (2012) 1.61
Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci (2011) 1.37
Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. Int J Cardiol (2014) 1.21
Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation (2013) 1.02
Hypertension in the elderly. World J Cardiol (2012) 0.89
Prognostic value of cardiovascular disease status: the Leiden 85-plus study. Age (Dordr) (2012) 0.86
Treatment of systemic hypertension. Am J Cardiovasc Dis (2012) 0.83
Modulation of circulating macrophage migration inhibitory factor in the elderly. Biomed Res Int (2014) 0.83
Relationship of Blood Pressure With Mortality and Cardiovascular Events Among Hypertensive Patients aged ≥60 years in Rural Areas of China: A Strobe-Compliant Study. Medicine (Baltimore) (2015) 0.83
Gender-stratified models to examine the relationship between financial hardship and self-reported oral health for older US men and women. Am J Public Health (2013) 0.81
Managing hypertension in the elderly: a common chronic disease with increasing age. Am Health Drug Benefits (2012) 0.81
The expression of the BPIFB4 and CXCR4 associates with sustained health in long-living individuals from Cilento-Italy. Aging (Albany NY) (2017) 0.81
Increasing complexity: which drug class to choose for treatment of hypertension in the elderly? Clin Interv Aging (2014) 0.79
Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Curr Hypertens Rep (2015) 0.77
Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol. BMJ Open (2014) 0.76
Inappropriate prescribing of antithrombotic therapy in Ethiopian elderly population using updated 2015 STOPP/START criteria: a cross-sectional study. Clin Interv Aging (2016) 0.75
Biochemical and molecular aspects of vascular adrenergic regulation of blood pressure in the elderly. Int J Hypertens (2011) 0.75
Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. BMJ (2015) 0.75
Inequalities in care in patients with acute myocardial infarction. World J Cardiol (2015) 0.75
Coenzyme Q10 prevents oxidative stress and fibrosis in isoprenaline induced cardiac remodeling in aged rats. BMC Pharmacol Toxicol (2017) 0.75
Longitudinal evaluation of medication underuse in older outpatients and its association with quality of life. Eur J Clin Pharmacol (2016) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23
Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 11.26
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med (1997) 10.68
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet (1999) 10.07
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation (2006) 10.05
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med (1999) 9.83
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet (1991) 9.57
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 8.77
Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet (1985) 8.35
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension (2008) 7.99
A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med (2003) 7.74
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet (1997) 7.46
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05
Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ (1992) 5.86
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (2001) 4.65
Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation (1998) 4.63
Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation (2000) 4.16
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol (1994) 4.08
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39
Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA (1998) 3.37
Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med (1994) 3.33
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol (2004) 3.23
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med (2007) 3.13
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation (2007) 2.82
Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med (2000) 2.68
Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol (1994) 2.50
Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) Circulation (1997) 2.34
Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med (1996) 2.28
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med (1998) 2.22
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation (2003) 2.20
Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med (2001) 1.97
Predictors of medication adherence in the elderly. Clin Ther (1998) 1.90
Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol (1977) 1.90
Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging (2005) 1.85
The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med (1988) 1.83
Hypertension and risk of stroke in an elderly population. Stroke (1974) 1.76
Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens (1992) 1.73
Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med (2000) 1.69
Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75+Study. Eur J Clin Pharmacol (2006) 1.49
Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J (2002) 1.47
Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med (1996) 1.46
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol (2010) 1.36
Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 1.27
Statin-fibrate combination therapy. Ann Pharmacother (2001) 1.21
Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf (2007) 1.20
New antithrombotic drugs. Clin Pharmacol Ther (2009) 1.15
Epidemiology and risk of hypertension in the elderly: the Framingham Study. J Hypertens Suppl (1988) 1.12
Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med (2000) 1.08
Shanghai trial of nifedipine in the elderly (STONE). J Hypertens (1996) 1.04
Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol (2001) 1.02
Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens (2009) 1.00
Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol (2004) 3.53
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation (2011) 1.97
Cardiac sarcoidosis: a comprehensive review. Arch Med Sci (2011) 1.61
Vascular complications after percutaneous coronary intervention following hemostasis with the Mynx vascular closure device versus the AngioSeal vascular closure device. J Invasive Cardiol (2010) 1.57
Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. Am J Cardiol (2006) 1.56
Angiotensin receptor blockers for management of hypertension. South Med J (2010) 1.54
Hyponatremia and cerebrovascular spasm in aneurysmal subarachnoid hemorrhage. Neurol India (2006) 1.54
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail (2010) 1.50
Predictors of mortality, rehospitalization for syncope, and cardiac syncope in 352 consecutive elderly patients with syncope. J Am Med Dir Assoc (2013) 1.49
A bridge too far: a critique of the new ACGME duty hour requirements. Am J Med (2012) 1.46
Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens (2015) 1.45
Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). Heart Dis (2003) 1.45
Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home. J Am Med Dir Assoc (2008) 1.43
Patients with infective endocarditis and increased cardiac troponin I levels have a higher incidence of in-hospital mortality and valve replacement than those with normal cardiac troponin I levels. Cardiology (2008) 1.41
Treatment of postmenopausal osteoporosis. Compr Ther (2007) 1.40
Prevalence of adequate and of optimal control of serum low-density lipoprotein cholesterol in an academic nursing home. J Am Med Dir Assoc (2007) 1.40
Hormone replacement therapy. An analysis of efficacy based on evidence. Geriatrics (2002) 1.40
Drug therapy of older persons with hypertension. J Am Med Dir Assoc (2006) 1.38
Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev (2010) 1.35
A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. Eur Heart J (2009) 1.34
Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J (2006) 1.32
Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. J Pharmacol Exp Ther (2007) 1.32
Intravascular device infections: epidemiology, diagnosis, and management. Cardiol Rev (2006) 1.30
Estrogen and progestin use and the QT interval in postmenopausal women. Ann Noninvasive Electrocardiol (2004) 1.27
A propensity-matched study of elevated jugular venous pressure and outcomes in chronic heart failure. Am J Cardiol (2009) 1.24
Association of interatrial block with development of atrial fibrillation. Am J Cardiol (2003) 1.22
Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol (2011) 1.19
Blood pressure j-curve: current concepts. Curr Hypertens Rep (2012) 1.18
A propensity-matched study of outcomes of chronic heart failure (HF) in younger and older adults. Arch Gerontol Geriatr (2008) 1.18
Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncope. Cardiol Rev (2007) 1.17
The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Curr Cardiovasc Risk Rep (2011) 1.17
ST-elevation myocardial infarction in the elderly--temporal trends in incidence, utilization of percutaneous coronary intervention and outcomes in the United States. Int J Cardiol (2013) 1.16
Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev (2014) 1.15
Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol (2015) 1.15
Cardiovascular complications of eating disorders. Cardiol Rev (2006) 1.15
Quality of care of nursing home residents hospitalized with heart failure. J Am Geriatr Soc (2002) 1.14
Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol (2005) 1.14
Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev (2003) 1.12
Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Arch Med Sci (2012) 1.12
Treatment of hypertension and prevention of ischemic stroke. Curr Cardiol Rep (2004) 1.11
Therapeutic options for severe asthma. Arch Med Sci (2012) 1.11
Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications. Cardiol Rev (2011) 1.09
Myocardial regeneration and stem cell repair. Curr Probl Cardiol (2008) 1.08
Risk factor reduction in progression of angiographic coronary artery disease. Arch Med Sci (2012) 1.08
Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol (2010) 1.08
Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema. Am J Ther (2007) 1.07
Not All NSTEMIs Are Created Equal. J Am Coll Cardiol (2015) 1.07
Prevalence of transthoracic echocardiographic abnormalities in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Arch Med Sci (2010) 1.07
Operationalizing the internal medicine milestones-an early status report. J Grad Med Educ (2013) 1.07
Prevalence of coronary artery disease, lower extremity peripheral arterial disease, and cerebrovascular disease in 110 men with an abdominal aortic aneurysm. Am J Cardiol (2004) 1.07
Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc (2014) 1.06
Protein kinase C in cardiac disease and as a potential therapeutic target. Cardiol Rev (2004) 1.06
Rheumatoid arthritis: cardiovascular manifestations, pathogenesis, and therapy. Curr Pharm Des (2012) 1.06
Peripheral venoarterial extracorporeal membrane oxygenation in combination with intra-aortic balloon counterpulsation in patients with cardiovascular compromise. Cardiology (2014) 1.05
Lipid, blood pressure and kidney update 2013. Int Urol Nephrol (2014) 1.05
Prevalence of valve calcium and association of valve calcium with coronary artery disease, atherosclerotic vascular disease, and all-cause mortality in 137 patients undergoing hemodialysis for chronic renal failure. Am J Cardiol (2005) 1.04
Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiol Rev (2009) 1.04
Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens (2010) 1.04
Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia. Cardiol Rev (2009) 1.04
Comparison of prevalence of atherosclerotic vascular disease in postmenopausal women with osteoporosis or osteopenia versus without osteoporosis or osteopenia. Am J Cardiol (2006) 1.04
Underuse of procedures for diagnosing osteoporosis and of therapies for osteoporosis in older nursing home residents. J Am Med Dir Assoc (2003) 1.04
Association of ankle-brachial index with severity of angiographic coronary artery disease in patients with peripheral arterial disease and coronary artery disease. Cardiology (2005) 1.03
Statin therapy in the elderly: a review. Arch Gerontol Geriatr (2009) 1.03
Carcinoid heart disease. Cardiol Rev (2012) 1.03
Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am J Med (2013) 1.03
The effects of off-normal hours, age, and gender for coronary angioplasty on hospital mortality in patients undergoing coronary angioplasty for acute myocardial infarction. Am J Cardiol (2004) 1.02
Prediction of moderate or severe pulmonary hypertension by main pulmonary artery diameter and main pulmonary artery diameter/ascending aorta diameter in pulmonary embolism. Cardiol Rev (2006) 1.01
U.S. medical students' perceptions of the adequacy of their schools' curricular attention to care at the end of life: 1998-2006. J Palliat Med (2008) 1.01
Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol (2009) 1.01
Cardiac and pericardial tumors. Cardiol Rev (2012) 1.01
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev (2007) 1.00
HDL metabolism and CETP inhibition. Cardiol Rev (2008) 1.00
Diagnosis of heart failure in older adults: predictive value of dyspnea at rest. Arch Gerontol Geriatr (2004) 1.00
Comparison of prevalence of unrecognized myocardial infarction and of silent myocardial ischemia detected by a treadmill exercise sestamibi stress test in patients with versus without diabetes mellitus. Am J Cardiol (2006) 1.00
Demographics and payment characteristics of nursing home residents in the United States: a 23-year trend. J Gerontol A Biol Sci Med Sci (2004) 1.00
A national survey of cardiovascular physicians' beliefs and clinical care practices when diagnosing and treating depression in patients with cardiovascular disease. Cardiol Rev (2006) 0.99
Cardiac amyloidosis: approaches to diagnosis and management. Cardiol Rev (2009) 0.99
Endothelin as a clinical target in the treatment of systemic hypertension. Cardiol Rev (2009) 0.98
The meaning of hypokalemia in heart failure. Int J Cardiol (2011) 0.98
Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis (2009) 0.98
Experience with faculty supervision of an electronic resident sign-out system. Am J Med (2010) 0.98
Double contrast-enhanced ultrasonography evaluation of preoperative Lauren classification of advanced gastric carcinoma. Arch Med Sci (2011) 0.98
Marijuana Use and Cardiovascular Disease. Cardiol Rev (2016) 0.97
Peripartum cardiomyopathy. Cardiol Rev (2005) 0.96
Isolated diastolic hypotension and incident heart failure in older adults. Hypertension (2011) 0.96
Thoracic aortic atheroma severity predicts high-risk coronary anatomy in patients undergoing transesophageal echocardiography. Arch Med Sci (2011) 0.96